VDI Cancer Panels are used in the diagnostic workup of cancer in dogs, cats, and horses. Using proliferation marker, Thymidine Kinase Type 1, and inflammatory markers C-Reactive Protein (dogs) or Haptoglobin (cats) the Cancer Panels are used for initial diagnosis of suspected cancer.
VDI Cancer Panels can be used for monitoring cancer progression and therapeutic response. Tracking both a proliferation marker and an inflammation marker, quantifies changes in disease over time - giving you insight to change before it’s clinically evident. Adjust therapy protocols that are ineffective, detect early signs of relapse, or simply monitor disease progression to determine proper time for intervention. VDI Cancer Panels make it simple to track changes in tumor processes.
The Cancer Panel is designed for the rule-in of malignancy using a marker of abnormal proliferation and a marker for inflammation. A positive Neoplasia Index™ is a rule-in for cancer. The Cancer Panel is not specific to any one type of cancer, but is specific for neoplasia, however sensitivity varies depending on tumor type, location, size, and activity. Once diagnosis is made, the Cancer Panel is a useful tool for monitoring disease progression or therapy efficacy.
A specific application of the Cancer Panel is the workup of GI distress in the cat. Differentiating GI LSA from IBD can be challenging. In conjunction with ultrasound, the Cancer Panel can rule in/rule out GI lymphoma in cats.
Pericardial Effusion presents a challenging problem for vets, as diagnosing the cause of the PE is risky. The Pericardial Effusion Panel takes pericardial fluid and serum, and evaluates the ratio of TK1. This ratio is a rule-out for neoplasia as the cause of the PE. No FNA needed.
Patients preparing to undergo stem cell therapy should be evaluated for occult cancer. Adding undifferentiated cells to a malignant process could cause growth of the tumor. The Pre-SCT Panel looks for signs of hidden cancer, giving you confidence the patient is safe to receive therapy. The Pre-SCT panel includes Hyaluronic Acid to set a baseline for post-therapeutic monitoring.
Thymidine Kinase Type 1 (TK1) has been shown to be an effective marker for lymphoma in horses. A
positive TK1 is a rule-in for cancer in the horse with suspected lymphoma.
Multi-marker integration is an effective way to improve diagnostic performance by combining independent markers, which are all affected by a disease process. The diagram illustrates how the union of TK1/CRP or HPT aids in the removal of false positives thus improving specificity (Neoplasia Index™). When the proliferation marker TK1 is elevated in conjunction with elevated inflammatory marker CRP (or HPT in cats), the likelihood of malignancy increases.
Neoplasia Index™ is a unitless score from 0 – 10.
VDI Laboratory, LLC
4685 Runway St. Ste K
Simi Valley, CA 93063